BDBM329982 US10463675, Example 66::US10980815, Ex. No. 66::US11197867, Example 66::US9663526, Example 65::US9663526, Example 66

SMILES FC1(F)CC1CN1[C@H]2CC[C@@H]1CN(C2)c1ccnc(Nc2cn[nH]c2)n1

InChI Key

Data  32 IC50

  Tab Delimited (TSV)   2D SDfile   Computed 3D by Vconf -m prep SDfile
Find this compound or compounds like it in BindingDB:
   Substructure
Similarity at least:  must be >=0.5
Exact match

Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB

Found 32 hits for monomerid = 329982   

TargetNon-receptor tyrosine-protein kinase TYK2(Human)
Pfizer

US Patent
LigandPNGBDBM329982(US9663526, Example 65 | US9663526, Example 66 | US...)
Affinity DataIC50: 22nMAssay Description:Compounds were added to a 384-well plate. Reaction mixtures contained 10 mM HEPES, pH 7.4, 10 mM MgCl2, 0.01% BSA, 0.0005% Tween 20, 1 mM ATP and 1 &...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/26/2021
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK3(Human)
Pfizer

US Patent
LigandPNGBDBM329982(US9663526, Example 65 | US9663526, Example 66 | US...)
Affinity DataIC50: 1.00E+4nMAssay Description:Compounds were added to a 384-well plate. Reaction mixtures contained 10 mM HEPES, pH 7.4, 10 mM MgCl2, 0.01% BSA, 0.0005% Tween 20, 1 mM ATP and 1 M...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/24/2022
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK2(Human)
Pfizer

US Patent
LigandPNGBDBM329982(US9663526, Example 65 | US9663526, Example 66 | US...)
Affinity DataIC50: 655nMAssay Description:Compounds were added to a 384-well plate. Reaction mixtures contained 10 mM HEPES, pH 7.4, 10 mM MgCl2, 0.01% BSA, 0.0005% Tween 20, 1 mM ATP and 1 M...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/24/2022
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK1(Human)
Pfizer

US Patent
LigandPNGBDBM329982(US9663526, Example 65 | US9663526, Example 66 | US...)
Affinity DataIC50: 106nMAssay Description:Compounds were added to a 384-well plate. Reaction mixtures contained 10 mM HEPES, pH 7.4, 10 mM MgCl2, 0.01% BSA, 0.0005% Tween 20, 1 mM ATP and 1 M...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/24/2022
Entry Details
Go to US Patent

TargetNon-receptor tyrosine-protein kinase TYK2(Human)
Pfizer

US Patent
LigandPNGBDBM329982(US9663526, Example 65 | US9663526, Example 66 | US...)
Affinity DataIC50: 65nMAssay Description:Compounds were added to a 384-well plate. Reaction mixtures contained 10 mM HEPES, pH 7.4, 10 mM MgCl2, 0.01% BSA, 0.0005% Tween 20, 1 mM ATP and 1 M...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/24/2022
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK3(Human)
Pfizer

US Patent
LigandPNGBDBM329982(US9663526, Example 65 | US9663526, Example 66 | US...)
Affinity DataIC50: 1.00E+4nMAssay Description:Compounds were added to a 384-well plate. Reaction mixtures contained 10 mM HEPES, pH 7.4, 10 mM MgCl2, 0.01% BSA, 0.0005% Tween 20, 1 mM ATP and 1 M...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/24/2022
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK2(Human)
Pfizer

US Patent
LigandPNGBDBM329982(US9663526, Example 65 | US9663526, Example 66 | US...)
Affinity DataIC50: 223nMAssay Description:Compounds were added to a 384-well plate. Reaction mixtures contained 10 mM HEPES, pH 7.4, 10 mM MgCl2, 0.01% BSA, 0.0005% Tween 20, 1 mM ATP and 1 M...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/24/2022
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK1(Human)
Pfizer

US Patent
LigandPNGBDBM329982(US9663526, Example 65 | US9663526, Example 66 | US...)
Affinity DataIC50: 35nMAssay Description:Compounds were added to a 384-well plate. Reaction mixtures contained 10 mM HEPES, pH 7.4, 10 mM MgCl2, 0.01% BSA, 0.0005% Tween 20, 1 mM ATP and 1 M...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/24/2022
Entry Details
Go to US Patent

TargetNon-receptor tyrosine-protein kinase TYK2(Human)
Pfizer

US Patent
LigandPNGBDBM329982(US9663526, Example 65 | US9663526, Example 66 | US...)
Affinity DataIC50: 22nMAssay Description:Compounds were added to a 384-well plate. Reaction mixtures contained 10 mM HEPES, pH 7.4, 10 mM MgCl2, 0.01% BSA, 0.0005% Tween 20, 1 mM ATP and 1 M...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/24/2022
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK3(Human)
Pfizer

US Patent
LigandPNGBDBM329982(US9663526, Example 65 | US9663526, Example 66 | US...)
Affinity DataIC50: 1.00E+4nMAssay Description:Compounds were added to a 384-well plate. Reaction mixtures contained 10 mM HEPES, pH 7.4, 10 mM MgCl2, 0.01% BSA, 0.0005% Tween 20, 1 mM ATP and 1 &...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/26/2021
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK2(Human)
Pfizer

US Patent
LigandPNGBDBM329982(US9663526, Example 65 | US9663526, Example 66 | US...)
Affinity DataIC50: 655nMAssay Description:Compounds were added to a 384-well plate. Reaction mixtures contained 10 mM HEPES, pH 7.4, 10 mM MgCl2, 0.01% BSA, 0.0005% Tween 20, 1 mM ATP and 1 &...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/26/2021
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK1(Human)
Pfizer

US Patent
LigandPNGBDBM329982(US9663526, Example 65 | US9663526, Example 66 | US...)
Affinity DataIC50: 106nMAssay Description:Compounds were added to a 384-well plate. Reaction mixtures contained 10 mM HEPES, pH 7.4, 10 mM MgCl2, 0.01% BSA, 0.0005% Tween 20, 1 mM ATP and 1 &...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/26/2021
Entry Details
Go to US Patent

TargetNon-receptor tyrosine-protein kinase TYK2(Human)
Pfizer

US Patent
LigandPNGBDBM329982(US9663526, Example 65 | US9663526, Example 66 | US...)
Affinity DataIC50: 65nMAssay Description:Compounds were added to a 384-well plate. Reaction mixtures contained 10 mM HEPES, pH 7.4, 10 mM MgCl2, 0.01% BSA, 0.0005% Tween 20, 1 mM ATP and 1 &...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/26/2021
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK3(Human)
Pfizer

US Patent
LigandPNGBDBM329982(US9663526, Example 65 | US9663526, Example 66 | US...)
Affinity DataIC50: 1.00E+4nMAssay Description:Compounds were added to a 384-well plate. Reaction mixtures contained 10 mM HEPES, pH 7.4, 10 mM MgCl2, 0.01% BSA, 0.0005% Tween 20, 1 mM ATP and 1 &...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/26/2021
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK2(Human)
Pfizer

US Patent
LigandPNGBDBM329982(US9663526, Example 65 | US9663526, Example 66 | US...)
Affinity DataIC50: 223nMAssay Description:Compounds were added to a 384-well plate. Reaction mixtures contained 10 mM HEPES, pH 7.4, 10 mM MgCl2, 0.01% BSA, 0.0005% Tween 20, 1 mM ATP and 1 &...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/26/2021
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK1(Human)
Pfizer

US Patent
LigandPNGBDBM329982(US9663526, Example 65 | US9663526, Example 66 | US...)
Affinity DataIC50: 35nMAssay Description:Compounds were added to a 384-well plate. Reaction mixtures contained 10 mM HEPES, pH 7.4, 10 mM MgCl2, 0.01% BSA, 0.0005% Tween 20, 1 mM ATP and 1 &...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/26/2021
Entry Details
Go to US Patent

TargetNon-receptor tyrosine-protein kinase TYK2(Human)
Pfizer

US Patent
LigandPNGBDBM329982(US9663526, Example 65 | US9663526, Example 66 | US...)
Affinity DataIC50: 22nMAssay Description:Compounds were added to a 384-well plate. Reaction mixtures contained 10 mM HEPES, pH 7.4, 10 mM MgCl2, 0.01% BSA, 0.0005% Tween 20, 1 mM ATP and 1 &...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/4/2019
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK3(Human)
Pfizer

US Patent
LigandPNGBDBM329982(US9663526, Example 65 | US9663526, Example 66 | US...)
Affinity DataIC50: 1.00E+4nMAssay Description:Compounds were added to a 384-well plate. Reaction mixtures contained 10 mM HEPES, pH 7.4, 10 mM MgCl2, 0.01% BSA, 0.0005% Tween 20, 1 mM ATP and 1 &...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/8/2020
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK2(Human)
Pfizer

US Patent
LigandPNGBDBM329982(US9663526, Example 65 | US9663526, Example 66 | US...)
Affinity DataIC50: 655nMAssay Description:Compounds were added to a 384-well plate. Reaction mixtures contained 10 mM HEPES, pH 7.4, 10 mM MgCl2, 0.01% BSA, 0.0005% Tween 20, 1 mM ATP and 1 &...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/8/2020
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK1(Human)
Pfizer

US Patent
LigandPNGBDBM329982(US9663526, Example 65 | US9663526, Example 66 | US...)
Affinity DataIC50: 106nMAssay Description:Compounds were added to a 384-well plate. Reaction mixtures contained 10 mM HEPES, pH 7.4, 10 mM MgCl2, 0.01% BSA, 0.0005% Tween 20, 1 mM ATP and 1 &...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/8/2020
Entry Details
Go to US Patent

TargetNon-receptor tyrosine-protein kinase TYK2(Human)
Pfizer

US Patent
LigandPNGBDBM329982(US9663526, Example 65 | US9663526, Example 66 | US...)
Affinity DataIC50: 65nMAssay Description:Compounds were added to a 384-well plate. Reaction mixtures contained 10 mM HEPES, pH 7.4, 10 mM MgCl2, 0.01% BSA, 0.0005% Tween 20, 1 mM ATP and 1 &...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/8/2020
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK3(Human)
Pfizer

US Patent
LigandPNGBDBM329982(US9663526, Example 65 | US9663526, Example 66 | US...)
Affinity DataIC50: 1.00E+4nMAssay Description:Compounds were added to a 384-well plate. Reaction mixtures contained 10 mM HEPES, pH 7.4, 10 mM MgCl2, 0.01% BSA, 0.0005% Tween 20, 1 mM ATP and 1 &...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/8/2020
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK2(Human)
Pfizer

US Patent
LigandPNGBDBM329982(US9663526, Example 65 | US9663526, Example 66 | US...)
Affinity DataIC50: 223nMAssay Description:Compounds were added to a 384-well plate. Reaction mixtures contained 10 mM HEPES, pH 7.4, 10 mM MgCl2, 0.01% BSA, 0.0005% Tween 20, 1 mM ATP and 1 &...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/8/2020
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK1(Human)
Pfizer

US Patent
LigandPNGBDBM329982(US9663526, Example 65 | US9663526, Example 66 | US...)
Affinity DataIC50: 35nMAssay Description:Compounds were added to a 384-well plate. Reaction mixtures contained 10 mM HEPES, pH 7.4, 10 mM MgCl2, 0.01% BSA, 0.0005% Tween 20, 1 mM ATP and 1 &...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/8/2020
Entry Details
Go to US Patent

TargetNon-receptor tyrosine-protein kinase TYK2(Human)
Pfizer

US Patent
LigandPNGBDBM329982(US9663526, Example 65 | US9663526, Example 66 | US...)
Affinity DataIC50: 22nMAssay Description:Compounds were added to a 384-well plate. Reaction mixtures contained 10 mM HEPES, pH 7.4, 10 mM MgCl2, 0.01% BSA, 0.0005% Tween 20, 1 mM ATP and 1 &...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/8/2020
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK3(Human)
Pfizer

US Patent
LigandPNGBDBM329982(US9663526, Example 65 | US9663526, Example 66 | US...)
Affinity DataIC50: 1.00E+4nMMore data for this Ligand-Target Pair
In Depth
Date in BDB:
6/4/2019
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK2(Human)
Pfizer

US Patent
LigandPNGBDBM329982(US9663526, Example 65 | US9663526, Example 66 | US...)
Affinity DataIC50: 655nMMore data for this Ligand-Target Pair
In Depth
Date in BDB:
6/4/2019
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK1(Human)
Pfizer

US Patent
LigandPNGBDBM329982(US9663526, Example 65 | US9663526, Example 66 | US...)
Affinity DataIC50: 106nMMore data for this Ligand-Target Pair
In Depth
Date in BDB:
6/4/2019
Entry Details
Go to US Patent

TargetNon-receptor tyrosine-protein kinase TYK2(Human)
Pfizer

US Patent
LigandPNGBDBM329982(US9663526, Example 65 | US9663526, Example 66 | US...)
Affinity DataIC50: 65nMAssay Description:Compounds were added to a 384-well plate. Reaction mixtures contained 10 mM HEPES, pH 7.4, 10 mM MgCl2, 0.01% BSA, 0.0005% Tween 20, 1 mM ATP and 1 &...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/4/2019
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK3(Human)
Pfizer

US Patent
LigandPNGBDBM329982(US9663526, Example 65 | US9663526, Example 66 | US...)
Affinity DataIC50: 1.00E+4nMMore data for this Ligand-Target Pair
In Depth
Date in BDB:
6/4/2019
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK2(Human)
Pfizer

US Patent
LigandPNGBDBM329982(US9663526, Example 65 | US9663526, Example 66 | US...)
Affinity DataIC50: 223nMMore data for this Ligand-Target Pair
In Depth
Date in BDB:
6/4/2019
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK1(Human)
Pfizer

US Patent
LigandPNGBDBM329982(US9663526, Example 65 | US9663526, Example 66 | US...)
Affinity DataIC50: 35nMMore data for this Ligand-Target Pair
In Depth
Date in BDB:
6/4/2019
Entry Details
Go to US Patent